On the basis of the cardiovascular protective role of SGLT2i and GLP1-RA, the European Association for the Study of Diabetes, the American Diabetes Association [92], and the American College of Cardiology [93] recommend considering these pharmacological classes as add-on therapies in patients with type 2 diabetes and atherosclerosis disease, preferring SGLT2i in patients with history of HF or at high risk of developing HF. The gene discussed is GLP1R; the disease is hydrops fetalis.